Therapeutic Pipeline in Nonalcoholic Steatohepatitis

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2021 Feb 11

PMID 33568794

Citations 107

Authors

Raj Vuppalanchi

Mazen Noureddin

Naim Alkhouri

Arun J Sanyal

Affiliations

Soon will be listed here.

Abstract

Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance rapidly. Accordingly, the field has moved from describing the clinical phenotype through the presence of nonalcoholic steatohepatitis (NASH) and degree of fibrosis to deep phenotyping with a description of associated comorbidities, genetic polymorphisms and environmental influences that could be associated with disease progression. These insights have fuelled a robust therapeutic pipeline across a variety of new targets to resolve steatohepatitis or reverse fibrosis, or both. Additionally, some of these therapies have beneficial effects that extend beyond the liver, such as effects on glycaemic control, lipid profile and weight loss. In addition, emerging therapies for NASH cirrhosis would have to demonstrate either reversal of fibrosis with associated reduction in portal hypertension or at least delay the progression with eventual decrease in liver-related outcomes. For non-cirrhotic NASH, it is the expectation that reversal of fibrosis by one stage or resolution of NASH with no worsening in fibrosis will need to be accompanied by overall survival benefits. In this Review, we summarize NASH therapies that have progressed to phase II and beyond. We also discuss some of the potential clinical challenges with the use of these new therapies when approved.

Citing Articles

A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta-Analysis.

Pennisi G, Di Maria G, Enea M, Vaccaro M, Celsa C, Antonucci M Liver Int. 2025; 45(4):e70056.

PMID: 40066918 PMC: 11894919. DOI: 10.1111/liv.70056.

From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.

Porada M, Buldak L Metabolites. 2025; 15(2).

PMID: 39997697 PMC: 11857179. DOI: 10.3390/metabo15020072.

Ebastine-mediated destabilization of E3 ligase MKRN1 protects against metabolic dysfunction-associated steatohepatitis.

Kim S, Han H, Rho H, Kang S, Mukherjee S, Kim J Cell Mol Life Sci. 2025; 82(1):66.

PMID: 39888429 PMC: 11785899. DOI: 10.1007/s00018-024-05535-2.

Potential therapeutic strategies for MASH: from preclinical to clinical development.

Xie Z, Li Y, Cheng L, Huang Y, Rao W, Shi H Life Metab. 2025; 3(5):loae029.

PMID: 39872142 PMC: 11749562. DOI: 10.1093/lifemeta/loae029.

MAP17 is a Novel NASH Progression Biomarker Associated with Macrophage Infiltration, Immunotherapy Response, and Oxidative Stress.

Huang Z, Chen J, Liu S, Xiang X, Long Y, Tan P J Inflamm Res. 2025; 18():601-619.

PMID: 39839187 PMC: 11747966. DOI: 10.2147/JIR.S497737.

References

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

Shirazi F, Wang J, Wong R . Nonalcoholic Steatohepatitis Becomes the Leading Indication for Liver Transplant Registrants Among US Adults Born Between 1945 and 1965. J Clin Exp Hepatol. 2020; 10(1):30-36. PMC: 6995884. DOI: 10.1016/j.jceh.2019.06.007. View

Younossi Z . Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2018; 70(3):531-544. DOI: 10.1016/j.jhep.2018.10.033. View

Shingina A, DeWitt P, Dodge J, Biggins S, Gralla J, Sprague D . Future Trends in Demand for Liver Transplant: Birth Cohort Effects Among Patients With NASH and HCC. Transplantation. 2018; 103(1):140-148. DOI: 10.1097/TP.0000000000002497. View

Haldar D, Kern B, Hodson J, Armstrong M, Adam R, Berlakovich G . Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. J Hepatol. 2019; 71(2):313-322. PMC: 6656693. DOI: 10.1016/j.jhep.2019.04.011. View

Calzadilla-Bertot L, Jeffrey G, Jacques B, McCaughan G, Crawford M, Angus P . Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand. Liver Transpl. 2019; 25(1):25-34. DOI: 10.1002/lt.25361. View

Noureddin M, Vipani A, Bresee C, Todo T, Kim I, Alkhouri N . NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018; 113(11):1649-1659. PMC: 9083888. DOI: 10.1038/s41395-018-0088-6. View

Holmer M, Melum E, Isoniemi H, Ericzon B, Castedal M, Nordin A . Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. Liver Int. 2018; 38(11):2082-2090. DOI: 10.1111/liv.13751. View

10.

Parthasarathy G, Revelo X, Malhi H . Pathogenesis of Nonalcoholic Steatohepatitis: An Overview. Hepatol Commun. 2020; 4(4):478-492. PMC: 7109346. DOI: 10.1002/hep4.1479. View

11.

Noureddin M, Sanyal A . Pathogenesis of NASH: The Impact of Multiple Pathways. Curr Hepatol Rep. 2019; 17(4):350-360. PMC: 6677539. DOI: 10.1007/s11901-018-0425-7. View

12.

Friedman S, Neuschwander-Tetri B, Rinella M, Sanyal A . Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018; 24(7):908-922. PMC: 6553468. DOI: 10.1038/s41591-018-0104-9. View

13.

Chalasani N, Guo X, Loomba R, Goodarzi M, Haritunians T, Kwon S . Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease. Gastroenterology. 2010; 139(5):1567-76, 1576.e1-6. PMC: 2967576. DOI: 10.1053/j.gastro.2010.07.057. View

14.

Eslam M, Valenti L, Romeo S . Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2017; 68(2):268-279. DOI: 10.1016/j.jhep.2017.09.003. View

15.

Unalp-Arida A, Ruhl C . Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population. Hepatology. 2019; 71(3):820-834. DOI: 10.1002/hep.31032. View

16.

Trepo E, Valenti L . Update on NAFLD genetics: From new variants to the clinic. J Hepatol. 2020; 72(6):1196-1209. DOI: 10.1016/j.jhep.2020.02.020. View

17.

Singh S, Allen A, Wang Z, Prokop L, Murad M, Loomba R . Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2014; 13(4):643-54.e1-9. PMC: 4208976. DOI: 10.1016/j.cgh.2014.04.014. View

18.

Kleiner D, Brunt E, Wilson L, Behling C, Guy C, Contos M . Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019; 2(10):e1912565. PMC: 6784786. DOI: 10.1001/jamanetworkopen.2019.12565. View

19.

Sanyal A, Harrison S, Ratziu V, Abdelmalek M, Diehl A, Caldwell S . The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 2019; 70(6):1913-1927. DOI: 10.1002/hep.30664. View

20.

Dulai P, Singh S, Patel J, Soni M, Prokop L, Younossi Z . Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017; 65(5):1557-1565. PMC: 5397356. DOI: 10.1002/hep.29085. View